Bristol tax reporting (correction)
Bristol-Myers Squibb's incoming tax reporting controls remain a "reportable condition," according to the company's auditors, PricewaterhouseCoopers. In a story on Bristol's latest earnings restatement, "The Pink Sheet" incorrectly reported that the tax controls are considered a "material weakness." Bristol has resolved both "material weaknesses" identified by PwC a year ago (1"The Pink Sheet" March 22, 2004, p. 24)...
You may also be interested in...
Bristol-Myers Squibb still has work to do to resolve its income tax reporting processes, the company acknowledged in a 10-K filed with the Securities & Exchange Commission March 15
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.